Key risks
- High valuation at PE 64.2 prices in significant earnings growth expectations; verify if underlying revenue and profit momentum can justify this multiple
- Operating margin of 8.42% is thin, leaving minimal cushion against input cost inflation, price competition, or operational disruption
- ROE of 12.73% is modest, indicating capital is not being deployed with high efficiency relative to peers in growing healthcare sectors
- FII ownership at 0.15% is extremely low; verify what deters institutional investors—whether scale constraints, governance, profitability trajectory, or disclosure practices
Generated analysis · source review pending